MedPath

Vakzine Projekt Management GmbH

Vakzine Projekt Management GmbH logo
🇩🇪Germany
Ownership
Subsidiary
Established
2002-01-01
Employees
-
Market Cap
-
Website
http://www.vakzine-manager.de

Clinical Trials

8

Active:3
Completed:4

Trial Phases

3 Phases

Phase 1:5
Phase 2:1
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (62.5%)
Phase 3
2 (25.0%)
Phase 2
1 (12.5%)

Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Phase 3
Completed
Conditions
Infection, Respiratory Tract
First Posted Date
2020-06-17
Last Posted Date
2021-10-26
Lead Sponsor
Vakzine Projekt Management GmbH
Target Recruit Count
2038
Registration Number
NCT04435379
Locations
🇩🇪

Hautarztpraxis Dres. Leitz & Kollegen, Stuttgart, Baden-Württemberg, Germany

🇩🇪

MECS Cottbus GmbH, Cottbus, Brandenburg, Germany

🇩🇪

Studienzentrum Dr. Keller, Frankfurt, Hessen, Germany

and more 9 locations

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Phase 3
Conditions
Infection, Respiratory Tract
First Posted Date
2020-05-13
Last Posted Date
2020-09-30
Lead Sponsor
Vakzine Projekt Management GmbH
Target Recruit Count
59
Registration Number
NCT04387409
Locations
🇩🇪

Ludwig-Maximilians-Universität München, München, Bayern, Germany

🇩🇪

Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany

🇩🇪

SocraTec R&D GmbH, Erfurt, Thüringen, Germany

Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa

Phase 2
Completed
Conditions
Tuberculosis
First Posted Date
2011-11-28
Last Posted Date
2013-10-29
Lead Sponsor
Vakzine Projekt Management GmbH
Target Recruit Count
48
Registration Number
NCT01479972
Locations
🇿🇦

Children's Infectious Diseases Clinical Research Unit, Tygerberg Hospital, Cape Town, South Africa

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa

Phase 1
Completed
Conditions
Tuberculosis
First Posted Date
2010-04-29
Last Posted Date
2011-11-21
Lead Sponsor
Vakzine Projekt Management GmbH
Target Recruit Count
24
Registration Number
NCT01113281
Locations
🇿🇦

Farmovs-Parexel, Bloemfontein, South Africa

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers

Phase 1
Completed
Conditions
Tuberculosis
Healthy
First Posted Date
2008-09-09
Last Posted Date
2010-05-20
Lead Sponsor
Vakzine Projekt Management GmbH
Target Recruit Count
80
Registration Number
NCT00749034
Locations
🇩🇪

Focus Clinical Drug Development GmbH, Neuss, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.